Quest Diagnostics Jumps 8% After Raising 2026 Guidance, Boosting Buybacks
Quest Diagnostics reported Q2 2026 revenue of $3,043 million and diluted EPS of $2.84, raised its full-year 2026 guidance, and repurchased 522,436 shares for $100 million. The stock rose 8.2%.
Key Numbers
Quest Diagnostics (NYSE: DGX) reported its second-quarter 2026 financial results earlier this week, posting revenue of $3,043 million and diluted earnings per share (EPS) of $2.84. The company raised its full-year 2026 guidance and continued its share buyback program, sending the stock up 8.2%.
Key Financial Results
| Metric | Value |
|---|---|
| Revenue (Q2 2026) | $3,043 million |
| Diluted EPS (Q2 2026) | $2.84 |
| FY 2026 Revenue Guidance (Low) | $11.95 billion |
| FY 2026 Revenue Guidance (High) | $12.05 billion |
| FY 2026 EPS Guidance (Low) | $9.97 |
| FY 2026 EPS Guidance (High) | $10.17 |
| Shares Repurchased in Q2 | 522,436 |
| Value of Buyback | $100 million |
Highlights from the Release
- Guidance Raise: The company increased its full-year 2026 revenue guidance to a range of $11.95-$12.05 billion and raised its EPS guidance to $9.97-$10.17.
- Share Buybacks: Quest continued its long-standing capital return program, repurchasing 522,436 shares for $100 million in the quarter, which supports EPS growth.
- Operational Strength: The strong performance was driven by higher demand for advanced diagnostics and growing test volumes.
Future Guidance
Quest Diagnostics expects full-year 2026 revenue between $11.95 billion and $12.05 billion, with diluted EPS in the range of $9.97 to $10.17, reflecting confidence in continued operational momentum.
Impact on the Stock
Shares of Quest Diagnostics (DGX) rose 8.2% following the earnings release and guidance raise, indicating investor optimism about the company's performance and capital return strategy.
What This Means for Investors
The guidance raise and ongoing buyback program underscore Quest Diagnostics' strong operational performance and commitment to shareholder returns. However, investors should monitor trends in diagnostic demand and competitive dynamics in the healthcare sector.
Frequently Asked Questions
Found this useful? Share it